Survival Benefit With Triple Therapy for Severe COVID-19

THURSDAY, Aug. 11, 2022 -- For patients with severe COVID-19 requiring high flow nasal cannula (HFNC), triple therapy of dexamethasone, remdesivir, and baricitinib is associated with significant survival benefit compared with dual therapy, according...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news